|
The Madrina Network Web Portal
|
5R44CA177037-03
|
$688,585
|
|
MATIELLA, ANA
|
ACMA SOCIAL MARKETING
|
|
Minimally invasive image-guided tumor ablation in an oncogenic pig model
|
5R21CA195433-02
|
$266,380
|
|
BURDETTE, EVERETTE
|
ACOUSTIC MEDSYSTEMS, INC.
|
|
Modulation of Immune Checkpoints by Self-Deliverable RNAi for Adoptive Cell Transfer
|
1R43CA213632-01
|
$231,500
|
|
WOLFSON, ALEXEY
|
ADVANCED RNA TECHNOLOGIES, LLC
|
|
Age and Diet: Major interacting factors that drive sporadic intestinal cancer
|
5R01CA174432-05
|
$660,173
|
|
AUGENLICHT, LEONARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The sequence recognition, structure and function of the IMP family of mRNA binding proteins
|
1F30CA214009-01A1
|
$49,044
|
|
BISWAS, JEETAYU
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Designing Novel Anti-Cancer Therapeutics: Targeting Methionine Metabolism
|
1F30CA210372-01A1
|
$49,044
|
|
FIRESTONE, ROSS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
PI3K Isoform Dependence in Adult Hematopoiesis and Myeloid Leukemia
|
5R01CA196973-02
|
$409,153
|
|
GRITSMAN, KIRA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Roles of formins in breast cancer invasion
|
5R21CA205262-02
|
$217,935
|
|
HODGSON, LOUIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
The B7x pathway in the tumor microenvironment
|
5R01CA175495-05
|
$346,525
|
|
ZANG, XINGXING
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Establishment of a patient-like mouse models of soft-tissue sarcoma sub-types
|
1R43CA213649-01
|
$224,700
|
|
HOFFMAN, ROBERT
|
ANTICANCER, INC.
|
|
Novel Androgen Receptor Degraders to Treat Castration-Resistant Prostate Cancer
|
5R44CA203199-02
|
$402,226
|
|
TAYLOR, IAN
|
ARVINAS, INC.
|
|
AML-MutationCounter, a tool to detect residual and recurrent leukemia
|
1R41CA213690-01
|
$220,087
|
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
P53 inactivation on MDSC development and tumor progression
|
5R01CA169133-05
|
$315,400
|
|
CUI, YAN
|
AUGUSTA UNIVERSITY
|
|
Allogeneic antibody therapy for malignant mesothelioma
|
5R03CA205713-02
|
$79,250
|
|
BURT, BRYAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
A CD47-blocking oncolytic vaccinia virus for cancer therapy
|
5F30CA203270-02
|
$44,044
|
|
CAO, FELICIA
|
BAYLOR COLLEGE OF MEDICINE
|
|
A Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis
|
1R01CA204926-01A1
|
$362,569
|
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics
|
1R01CA205594-01A1
|
$362,569
|
|
LI, YI
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-12
|
$249,637
|
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Managing chemotherapy induced neuropathy in Cancer patients using ExerGaming
|
5R21CA190933-02
|
$199,119
|
|
NAJAFI, BIJAN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Metabolic Regulation in Leukemia-Initatiating Cells
|
5R01CA193235-03
|
$462,191
|
|
NAKADA, DAISUKE
|
BAYLOR COLLEGE OF MEDICINE
|
|
High-Throughput Functional Annotation of Fusion Gene Cancer Drivers
|
5R21CA198320-02
|
$207,235
|
|
SCOTT, KENNETH
|
BAYLOR COLLEGE OF MEDICINE
|
|
Reprogramming of Prostate Stromal Cells by Prostate Inflammation
|
5R21CA196570-02
|
$185,247
|
|
XIN, LI
|
BAYLOR COLLEGE OF MEDICINE
|
|
METHYLATION BIOMARKER DEVELOPMENT FOR NONINVASIVE DETECTION OF COLORECTAL CANCER
|
5R01CA181572-04
|
$315,983
|
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Integrating Palliative Oncology Care into Doctor of Nursing Practice Programs
|
5R25CA171960-05
|
$260,812
|
|
FERRELL, BETTY
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Training Healthcare Professionals to Implement Biopsychosocial Screening
|
5R25CA174444-05
|
$277,797
|
|
LOSCALZO, MATTHEW
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Pharmacological modulation of epigenetic changes in AML
|
5R01CA102031-12
|
$342,107
|
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
|
5R01CA201496-02
|
$463,530
|
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Hyperpolarized NMR for Studies of Cancer Therapies Targeting the Warburg Effect
|
5R01CA169470-05
|
$361,050
|
|
GRANT, AARON
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
MiR-199~214 cluster at the crossroads of plasticity and malignancy in breastcancer
|
1R01CA207322-01A1
|
$395,738
|
|
KARNOUB, ANTOINE
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Cbx-3/HP-1gamma deficiency confers anti-tumor immunity
|
5R21CA198263-02
|
$225,765
|
|
THAI, TO-HA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Rapid detection of minimal residual disease in acute myeloid leukemia from peripheral blood
|
1R44CA213595-01
|
$798,225
|
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
Defining driver tumor-suppressors for melanoma using the zebrafish
|
5K99CA201465-02
|
$171,990
|
|
ABLAIN, JULIEN
|
BOSTON CHILDREN'S HOSPITAL
|
|
Structure and Assembly of Viruses
|
5R01CA013202-46
|
$384,600
|
|
HARRISON, STEPHEN
|
BOSTON CHILDREN'S HOSPITAL
|
|
(PQA2): Escape from breast tumor dormancy: convergence of obesity and menopause
|
5R01CA185530-04
|
$367,275
|
|
MOSES, MARSHA
|
BOSTON CHILDREN'S HOSPITAL
|
|
Development of diagnostic and prognostic tests for esophageal adenocarcinoma
|
1R01CA208599-01A1
|
$646,502
|
|
GODFREY, TONY
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Planning for NCDs Research Center of Excellence in Southern Africa
|
5P20CA210283-02
|
$236,966
|
$118,483
|
TAPELA, NEO
|
BOTSWANA-HARVARD AIDS INSTITUTE
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-04
|
$11,145,123
|
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Co-targeting oncogenic pathways in advanced prostate cancer
|
5R01CA198097-02
|
$381,212
|
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Selenoproteins as targets for cancer prevention
|
5R01CA080946-17
|
$316,004
|
|
GLADYSHEV, VADIM
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
De-Regulation of 5hmC/TET2 Tumor Suppressor under Anti-Estrogen Therapy
|
5R01CA194302-02
|
$405,036
|
|
SHI, YUJIANG
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Coordinating tumor differentiation and immune suppression with the metabolic state and treatment outcome
|
1R01CA207982-01A1
|
$411,278
|
|
WIDLUND, HANS
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Simultaneous Detection of Proteins and Whole Transcriptomes in Single Cells
|
1F32CA213966-01
|
$56,694
|
|
XU, ALEXANDER
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
Examining the role of the miR-181a:Wnt/B-catenin axis in ovarian cancer
|
5R01CA197780-02
|
$363,581
|
|
DIFEO, ANALISA
|
CASE WESTERN RESERVE UNIVERSITY
|
|
BORG: Role for a Novel lncRNA in Mediating Breast Cancer Metastasis and Dormancy
|
5F30CA203233-02
|
$49,044
|
|
GOODING, ALEX
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Small Molecule Induction of 15-PGDH: A Target in Colon Cancer Chemoprevention
|
5R01CA168586-05
|
$328,888
|
|
LETTERIO, JOHN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Defining the role of the PR72 regulatory subunit in small molecule mediated activation of PP2A's tumor suppressive activity
|
1F31CA213554-01
|
$37,644
|
|
PERL, ABBEY
|
CASE WESTERN RESERVE UNIVERSITY
|
|
SLX4IP and a novel regulatory network in breast cancer metastasis and dormancy
|
1F30CA213892-01
|
$44,044
|
|
ROBINSON, NATHANIEL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis
|
5R01CA177069-05
|
$328,265
|
|
SCHIEMANN, WILLIAM
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy
|
1R41CA213463-01
|
$300,000
|
|
SZABO, CSABA
|
CBS THERAPEUTICS, INC.
|
|
Differential MRI imaging for brain tumor metastases diagnosis and treatment monitoring
|
5R01CA188743-03
|
$511,546
|
|
LJUBIMOVA, JULIA
|
CEDARS-SINAI MEDICAL CENTER
|
Total relevant funding to Vascular Disease for this search: $1,987,916
|